CPT code 33249 covers implantation or replacement of a permanent implantable cardioverter-defibrillator (ICD) system with single- or dual-chamber transvenous leads. This procedure is a critical intervention for patients at risk of life-threatening ventricular arrhythmias and is central to sudden cardiac death prevention strategies nationwide. The code captures both initial device implantation and replacement of malfunctioning or infected systems when transvenous leads are used.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service settings, typical sites of service, and common operational considerations tied to coding and billing workflows. The publication outlines benchmark elements such as common modifiers and related service-line considerations where available and highlights national policy and coverage themes that influence access to ICD therapy.

This resource assists billing managers, electrophysiology program directors, and revenue cycle teams in understanding the clinical scope represented by CPT code 33249, the payer landscape nationally, and the types of documentation and service contexts typically associated with this code. Data not available in the input will be noted as such in relevant sections.